Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 20/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PRKACA | P17612 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | MARK3 | P27448 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.41 |
| ▸ | CLK2 | P49760 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | CDK7 | P50613 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2490162 | 0.90 | GSK3B (0.47) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL12207462 | 0.89 | GSK3B (0.47) | GSK3B | |
| SCHEMBL2489049 | 0.85 | GSK3B (0.41) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL2527052 | 0.85 | MAP4K4 (0.41) | GSK3BCYP1A2CYP2D6MAP4K4DYRK1A | |
| SCHEMBL2487968 | 0.85 | GSK3B (0.54) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL2489165 | 0.84 | GSK3B (0.42) | GSK3BCYP2D6 | |
| SCHEMBL3749271 | 0.83 | GSK3B (0.43) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL2488030 | 0.82 | GSK3B (0.48) | GSK3BCYP1A2CYP2D6ROCK2 | |
| SCHEMBL2489805 | 0.81 | GSK3B (0.45) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL2489903 | 0.81 | GSK3B (0.41) | GSK3BCYP1A2CYP2D6ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4778657-B2 | — | — | 2011-09-21 | — | — | JP | claimed |
| US-7378413-B2 | 2-amino-3-(alkyl)-pyrimidone derivatives | SANOFI AVENTIS (FR) | 2008-05-27 | — | — | US | claimed |
| EP-1276738-B8 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | SANOFI AVENTIS (FR) | 2008-02-20 | — | — | EP | claimed |
| EP-1276738-B1 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | SANOFI AVENTIS (FR) | 2007-12-12 | — | — | EP | claimed |
| CN-1891220-A | Use of 2-amino-3-alkylpyrimidinone derivatives for producing medicaments | SANOFI SYNTHELABO (FR) | 2007-01-10 | — | — | CN | claimed |
| CN-1247567-C | 2-amino-3-alkylpyrimidinone derivatives as GSK3 beta inhibitors | SANOFI AVENTIS (FR) | 2006-03-29 | — | — | CN | claimed |
| US-20050130998-A1 | 2-amino-3-(alkyl)-pyrimidone derivatives | SANOFI (FR) | 2005-06-16 | — | — | US | claimed |
| US-6844335-B2 | 2-amino-3-(alkyl)-pyrimidone derivatives as GSK3.β.inhibitors | SANOFI-SYNTHELABO (FR) | 2005-01-18 | — | — | US | claimed |
| US-20030187004-A1 | 2-Amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors | SANOFI (FR) | 2003-10-02 | — | — | US | claimed |
| EP-1276738-A1 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | Sanofi-Aventis (FR) | 2003-01-22 | — | — | EP | claimed |
| WO-2001070729-A1 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | SANOFI-SYNTHELABO (FR) | 2001-09-27 | — | — | WO | claimed |
| US-7378413-B2 | 2-amino-3-(alkyl)-pyrimidone derivatives | SANOFI AVENTIS (FR) | 2008-05-27 | — | — | US | disclosed |
| EP-1276738-B1 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | SANOFI AVENTIS (FR) | 2007-12-12 | — | — | EP | disclosed |
| CN-1891220-A | Use of 2-amino-3-alkylpyrimidinone derivatives for producing medicaments | SANOFI SYNTHELABO (FR) | 2007-01-10 | — | — | CN | disclosed |
| CN-1247567-C | 2-amino-3-alkylpyrimidinone derivatives as GSK3 beta inhibitors | SANOFI AVENTIS (FR) | 2006-03-29 | — | — | CN | disclosed |
| US-20050130998-A1 | 2-amino-3-(alkyl)-pyrimidone derivatives | SANOFI (FR) | 2005-06-16 | — | — | US | disclosed |
| US-6844335-B2 | 2-amino-3-(alkyl)-pyrimidone derivatives as GSK3.β.inhibitors | SANOFI-SYNTHELABO (FR) | 2005-01-18 | — | — | US | disclosed |
| US-20030187004-A1 | 2-Amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors | SANOFI (FR) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130998-A1 | 2-amino-3-(alkyl)-pyrimidone derivatives | GSK3A, GSK3B, PSEN2 | GSK3B 2/4885CYP1A2 727/4885CYP2D6 447/4885 |
| US-20030187004-A1 | 2-Amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors | GSK3A, GSK3B, CSNK2A3 | GSK3B 2/4885CYP1A2 1885/4885CYP2D6 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.